J Korean Ophthalmol Soc.  2023 Oct;64(10):981-985. 10.3341/jkos.2023.64.10.981.

Recovery from Upper Eyelid Sulcus Deepening Following Switch from Prostaglandin Analogues to EP2 Receptor Agonist

• Jeon YJ
• Jung JJ

• KMID: 2546822
• DOI: http://doi.org/10.3341/jkos.2023.64.10.981

Abstract

Purpose
To report a case of recovery from deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to an EP2 receptor agonist.
Case summary
A 65-year-old male patient with suspicion of glaucoma presented for detailed examinations. At the initial visit, his best-corrected visual acuity was 1.0 in both eyes, and the intraocular pressure (IOP) was 14/14 mmHg. Examination revealed no specific findings in the anterior segment, mild early cataracts bilaterally, and moderate glaucomatous changes. Therefore, bimatoprost/timolol fixed-combination eye drops were administered in both eyes. After 1 month, the IOP was 11/11 mmHg and no evidence of glaucoma progression was found. After 10 months, the IOP was 17/18 mmHg and there was deepening of the upper eyelid sulcus bilaterally. Consequently, bimatoprost/timolol fixed combination eye drops were switched to omidenepag isopropyl. Within 2 months of the switch, the deepening of the upper eyelid sulcus recovered completely and the IOP was 14/13 mmHg.
Conclusions
Patients with prostaglandin-associated periorbitopathy should be switched to non-prostaglandin drugs or EP2 receptor agonists. Our patient exhibited complete recovery of the upper eyelid sulcus deepening after switching to an EP2 agonist.

Keyword

EP2, Omidenepag isopropyl, PAP